PCM
CLBT icon

Pavaki Capital Management’s Cellebrite CLBT Stock Holding History

Pavaki Capital Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$876K Buy
+60,000
New +$793K 0.31% 60

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pavaki Capital Management's CLBT Position: Q2 2026 in Review

Pavaki Capital Management opened a new position in Cellebrite (CLBT) in Q2 2026: 60,000 shares worth $876K. The stake represents 0.31% of the portfolio and ranks #60 among its holdings.

186 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Pavaki Capital Management held 60,000 shares of Cellebrite worth $876K as of Q2 2026.
  • Cellebrite was a new Pavaki Capital Management position in Q2 2026.
  • Cellebrite made up 0.31% of Pavaki Capital Management's portfolio in Q2 2026, its #60 holding.
  • 186 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.